Business Wire

Tula Reveals Technology to Reduce CO2 by 11% in Mild Hybrid Diesel Vehicles

Share

Tula Technology, Inc., a leader in propulsion efficiency, has released the findings of a recent simulation study to evaluate the efficacy of its newest technology. The study validated that Tula’s Dynamic Skip Fire (DSF) developed for mild hybrid diesel vehicles reduced CO2 emissions in a 2.3 liter 4-cylinder 48-volt light commercial vehicle in challenging real-world conditions. When Tula’s software strategies were implemented, an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of only €200 ($235 USD) per vehicle.

For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.

“We created a synergistic technology by combining mild hybrid powertrain controls with our diesel Dynamic Skip Fire, which has proven to be very effective at reducing NOX (nitrogen oxides) and CO2 (carbon dioxide) emissions in heavy duty trucks,” said R. Scott Bailey, president and CEO of Tula Technologies. “We call it electrified diesel Dynamic Skip Fire, or edDSF, and it will help manufacturers of light commercial vehicles meet challenging NOX standards in a cost-effective manner. Equally significant, our product performs even better in tougher real-world conditions than under test cycles.”

FEV, an international engineering partner to the auto industry, joined forces with Tula to develop this study. Tula will present the results at the virtual Diesel Powertrains 3.0 Conference (https://fev-live.com/diesel/conference-program/) Wednesday, June 30, at 10:35 Paris (CEST) / 16:35 Beijing.

The findings show that electrified diesel Dynamic Skip Fire (edDSF) can significantly reduce CO2 output through the synergies created by pairing a hybrid system with DSF while also providing a means to achieve upcoming low-NOX targets aimed at decreasing the pollution created by internal combustion engines. Fuel savings are an additional benefit of edDSF compared to other emissions management technologies that typically require burning additional fuel to produce the heat required to decrease tailpipe emissions. The economics of edDSF are compelling—over a six-month period, an urban delivery vehicle equipped with edDSF will save enough in fuel expenses to recoup the costs associated with Tula’s technology.

Bailey concluded, “We are excited to present our findings at this global conference. With edDSF, we are offering a leading-edge solution to help meet the tight deadline the EU has set to reduce emissions, and for vehicle powertrain development, 2026 is just around the corner. edDSF is one of the many patented technologies in Tula’s portfolio that help improve the environment by increasing the efficiency of engines and motors while reducing harmful emissions. I am very proud of our outstanding engineering team for continuing to develop new applications for our state-of-the art control technologies.”

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 340 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tula Technology, Inc.
Ram Subramanian
Principal Marketing Strategist
ram@tulatech.com

Media:
Financial Profiles, Inc.
Debbie Douglas
Senior Vice President
ddouglas@finprofiles.com
(949) 375-3436

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye